Fingerprint
Dive into the research topics of 'Tixagevimab–cilgavimab for treatment of patients hospitalised with COVID-19: a randomised, double-blind, phase 3 trial'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
Tixagevimab–cilgavimab for treatment of patients hospitalised with COVID-19: a randomised, double-blind, phase 3 trial
ACTIV-3/Therapeutics for Inpatients with COVID-19 (TICO) Study Group, Henrik Nielsen (Member of study group), Rikke Krog Thisted (Member of study group), Kristine Toft Petersen (Member of study group), Maria Ruwald Juhl (Member of study group)
Research output: Contribution to journal › Journal article › Research › peer-review
78
Citations
(Scopus)